Light Chain Bioscience
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Light Chain Bioscience
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
- Antisense, Oligonucleotides
Drug Discovery Tools
- Other Names / Subsidiaries
- NovImmune SA